Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2021

View Archived Issues

New SUMO-activating enzyme subunit 1 inhibitors identified at Oncovalent Therapeutics

Icahn School of Medicine at Mount Sinai presents new arylsulfonamide derivatives

New NLRP3 inflammasome inhibitors patented by Roche, Genentech

Suzhou Ark Biopharmaceutical patents respiratory syncytial virus inhibitors

Rhenium-labeled nanoliposomes show efficacy in rat models of leptomeningeal disease

New delivery system SENDs therapeutic RNA without triggering immune system

Small-molecule degrader targets phospho-AKT and inhibits growth of PI3K/PTEN pathway mutant cancers

H3.3-K27M drives tumorigenesis in hindbrain NSCs through disruption of PRC2 and enhancer functions

Foghorn initiates first-in-human study of FHD-609 for synovial sarcoma

First-in-human data reported for [68Ga]iPSMA-BN in healthy subjects

Phase IIb study of izencitinib in ulcerative colitis misses primary endpoint

Bristol Myers Squibb identifies new lead BRD4 inhibitors

Completed phase I studies of ME-3183 pave way for phase II studies in plaque psoriasis

JadiCells show promise in animal model of COPD

Hepagene reports phase I data on FXR agonist HPG-1860

Jupiter Wellness submits pre-IND meeting request for JW-100 for eczema

Biallelic mutations in DNAH10 cause male infertility with asthenoteratozoospermia

BlueWillow announces interim phase I data on intranasal anthrax vaccine candidate BW-1010

Regeneron reports topline phase II results on 8-mg dose of aflibercept in wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...